| 臺大學術典藏 |
2021-04-23T05:56:24Z |
Clinical utility of plasma EGFR mutation detection with quantitative PCR in advanced lung cancer: A meta-analysis
|
Kok P.-S.;Lee K.;Lord S.;Chih-Hsin Yang;Rosell R.;Goto K.;John T.;Wu Y.-L.;Mok T.S.K.;Lee C.K.; Kok P.-S.; Lee K.; Lord S.; CHIH-HSIN YANG; Rosell R.; Goto K.; John T.; Wu Y.-L.; Mok T.S.K.; Lee C.K. |
| 臺大學術典藏 |
2020-05-26T09:26:46Z |
LBA1_PR: Osimertinib as first-line treatment for EGFR mutation-positive advanced NSCLC: updated efficacy and safety results from two Phase I expansion cohorts
|
J?nne P.A.;Ohe Y;Nogami N;John T;Kim D.-W;Kurata T;Lee C.K;Chih-Hsin Yang;Ramalingam S; Ramalingam S; CHIH-HSIN YANG; Lee C.K; Kurata T; Kim D.-W; John T; Nogami N; Ohe Y; Jänne P.A. |
| 臺大學術典藏 |
2020-05-26T09:26:46Z |
LBA1_PR: Osimertinib as first-line treatment for EGFR mutation-positive advanced NSCLC: updated efficacy and safety results from two Phase I expansion cohorts
|
J?nne P.A.;Ohe Y;Nogami N;John T;Kim D.-W;Kurata T;Lee C.K;Chih-Hsin Yang;Ramalingam S; Ramalingam S; CHIH-HSIN YANG; Lee C.K; Kurata T; Kim D.-W; John T; Nogami N; Ohe Y; Jänne P.A. |
| 臺大學術典藏 |
2020-05-26T09:26:30Z |
Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer
|
Ramalingam S.S; CHIH-HSIN YANG; Lee C.K; Kurata T; Kim D.-W; John T; Nogami N; Ohe Y; Mann H; Rukazenkov Y; Ghiorghiu S; Stetson D; Markovets A; Barrett J.C; Thress K.S; Jänne P.A.; J?nne P.A.;Thress K.S;Barrett J.C;Markovets A;Stetson D;Ghiorghiu S;Rukazenkov Y;Mann H;Ohe Y;Nogami N;John T;Kim D.-W;Kurata T;Lee C.K;Chih-Hsin Yang;Ramalingam S.S |
| 臺大學術典藏 |
2020-05-26T09:26:30Z |
Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer
|
Ramalingam S.S; CHIH-HSIN YANG; Lee C.K; Kurata T; Kim D.-W; John T; Nogami N; Ohe Y; Mann H; Rukazenkov Y; Ghiorghiu S; Stetson D; Markovets A; Barrett J.C; Thress K.S; Jänne P.A.; J?nne P.A.;Thress K.S;Barrett J.C;Markovets A;Stetson D;Ghiorghiu S;Rukazenkov Y;Mann H;Ohe Y;Nogami N;John T;Kim D.-W;Kurata T;Lee C.K;Chih-Hsin Yang;Ramalingam S.S |
| 臺大學術典藏 |
2020-05-25T07:35:14Z |
Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study
|
Yang J.C.-H.; Yang Z; Overend P; Kao S; Goldman J.W; Su W.-C; Natale R; Rabbie S; Harrop B; John T; Kim H.R; Chia-Chi Lin; Kim T.M; Ahn J.-S; Lee J.S; Kim S.-W; Cho B.C; Kim D.-W; Ahn M.-J |
| 臺大學術典藏 |
2020-05-25T07:35:06Z |
Entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of ALKA-372-001, STARTRK-1 and STARTRK-2
|
Barlesi F; Drilon A; De Braud F; Cho B.C; Ahn M.J; Siena S; Krebs M.G; Chia-Chi Lin; John T; Tan D.S.W; Seto T; Dziadziuszko R; Arkenau H.-T; Rolfo C; Wolf J; Ye C; Riehl T; Eng S; Doebele R.C. |
| 臺大學術典藏 |
2020-05-25T07:35:02Z |
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1�V2 trials
|
Rolfo C; de Braud F; Drilon A; Siena S; Dziadziuszko R; Barlesi F; Krebs M.G; Shaw A.T; Doebele R.C.;Wilson T.R;Eng S;Johnson A;Cui N;Simmons B;Chow-Maneval E;Riehl T;Prenen H;Tan D.S.W;Chia-Chi Lin;Murakami H;Otterson G.A;Chung C.H;Chae Y.K;Li Y.-C;Ohe Y;Kim S.-W;Arkenau H.-T;Karapetis C.S;Goto K;John T;Chiu C.-H;Patel M.R;Cho B.C;Seto T;Wolf J;Ahn M.-J;Rolfo C;de Braud F;Shaw A.T;Krebs M.G;Barlesi F;Dziadziuszko R;Siena S;Drilon A; Ahn M.-J; Wolf J; Seto T; Cho B.C; Patel M.R; Chiu C.-H; John T; Goto K; Karapetis C.S; Arkenau H.-T; Kim S.-W; Ohe Y; Li Y.-C; Chae Y.K; Chung C.H; Otterson G.A; Murakami H; Chia-Chi Lin; Tan D.S.W; Prenen H; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson T.R; Doebele R.C. |
| 臺大學術典藏 |
2020-05-25T07:35:02Z |
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1�V2 trials
|
Rolfo C; de Braud F; Drilon A; Siena S; Dziadziuszko R; Barlesi F; Krebs M.G; Shaw A.T; Doebele R.C.;Wilson T.R;Eng S;Johnson A;Cui N;Simmons B;Chow-Maneval E;Riehl T;Prenen H;Tan D.S.W;Chia-Chi Lin;Murakami H;Otterson G.A;Chung C.H;Chae Y.K;Li Y.-C;Ohe Y;Kim S.-W;Arkenau H.-T;Karapetis C.S;Goto K;John T;Chiu C.-H;Patel M.R;Cho B.C;Seto T;Wolf J;Ahn M.-J;Rolfo C;de Braud F;Shaw A.T;Krebs M.G;Barlesi F;Dziadziuszko R;Siena S;Drilon A; Ahn M.-J; Wolf J; Seto T; Cho B.C; Patel M.R; Chiu C.-H; John T; Goto K; Karapetis C.S; Arkenau H.-T; Kim S.-W; Ohe Y; Li Y.-C; Chae Y.K; Chung C.H; Otterson G.A; Murakami H; Chia-Chi Lin; Tan D.S.W; Prenen H; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson T.R; Doebele R.C. |
| 國立成功大學 |
2020 |
Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis
|
Papadimitrakopoulou, V.A.;Mok, T.S.;Han, J.-Y.;Ahn, M.-J.;Delmonte, A.;Ramalingam, S.S.;Kim, S.W.;Shepherd, F.A.;Laskin, J.;He, Y.;Akamatsu, H.;Theelen, W.S.M.E.;Su, W.-C.;John, T.;Sebastian, M.;Mann, H.;Miranda, Miranda M.;Laus, G.;Rukazenkov, Y.;Wu, Y.-L. |
| 國立成功大學 |
2018 |
EGFR mutation analysis for prospective patient selection in AURA3 phase III trial of osimertinib versus platinum-pemetrexed in patients with EGFR T790M-positive advanced non-small-cell lung cancer
|
John, T.;Akamatsu, H.;Delmonte, A.;Su, W.-C.;Lee, J.S.;Chang, G.-C.;Huang, X.;Jenkins, S.;Wu, Y.-L. |
| 臺大學術典藏 |
2017 |
Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study
|
Ahn M.-J; Kim D.-W; Cho B.C; Kim S.-W; Lee J.S; Ahn J.-S; Kim T.M; Lin C.-C; Kim H.R; John T; Kao S; Goldman J.W; Su W.-C; Natale R; Rabbie S; Harrop B; Overend P; Yang Z; CHIH-HSIN YANG; Chih-Hsin Yang;Yang Z;Overend P;Harrop B;Rabbie S;Natale R;Su W.-C;Goldman J.W;Kao S;John T;Kim H.R;Lin C.-C;Kim T.M;Ahn J.-S;Lee J.S;Kim S.-W;Cho B.C;Kim D.-W;Ahn M.-J |
| 臺大學術典藏 |
2017 |
Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study
|
Ahn M.-J; Kim D.-W; Cho B.C; Kim S.-W; Lee J.S; Ahn J.-S; Kim T.M; Lin C.-C; Kim H.R; John T; Kao S; Goldman J.W; Su W.-C; Natale R; Rabbie S; Harrop B; Overend P; Yang Z; CHIH-HSIN YANG; Chih-Hsin Yang;Yang Z;Overend P;Harrop B;Rabbie S;Natale R;Su W.-C;Goldman J.W;Kao S;John T;Kim H.R;Lin C.-C;Kim T.M;Ahn J.-S;Lee J.S;Kim S.-W;Cho B.C;Kim D.-W;Ahn M.-J |
| 國立成功大學 |
2017 |
Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study
|
Ahn, M.-J.;Kim, D.-W.;Cho, B.C.;Kim, S.-W.;Lee, J.S.;Ahn, J.-S.;Kim, T.M.;Lin, C.-C.;Kim, H.R.;John, T.;Kao, S.;Goldman, J.W.;Su, W.-C.;Natale, R.;Rabbie, S.;Harrop, B.;Overend, P.;Yang, Z.;Yang, J.C.-H. |
